Viking Therapeutics Starts Phase III Trials for Oral Obesity Pill VK2735

Key Facts

1Viking Therapeutics launched two Phase III studies of its oral VK2735 drug for obesity treatment.

2Previous Phase II results for the drug showed mean weight loss of up to 12.2%.

Viking Therapeutics launched two Phase III studies of its oral VK2735 drug for obesity treatment. Zacks reported that the move into advanced clinical development follows successful Phase II data which demonstrated a mean weight loss of up to 12.2%.

VKTX closed at $25.47 on October 14, 2026, with the stock reaching a day high of $26.89 and a low of $25.28. The company aims to strengthen its competitive position in the high-growth obesity drug sector, though long-term success remains subject to the final trial outcomes.